Reuters logo
BRIEF-Immune Design announced updated clinical, biomarker data for product candidates CMB305, G100
June 5, 2017 / 12:21 PM / 6 months ago

BRIEF-Immune Design announced updated clinical, biomarker data for product candidates CMB305, G100

June 5 (Reuters) - Immune Design Corp:

* Announced updated clinical and biomarker data for its lead immuno-oncology product candidates, CMB305 and G100

* Immune Design Corp - “CMB305 was well tolerated, with only one related grade 3 adverse event (AE)”

* Immune Design - in follicular NHL patients, intratumoral immunization with G100 induced objective responses (≥50% tumor reduction) in 44% of patients

* “G100 was well tolerated, with no related grade 3/4 AES in all three dose levels tested” Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below